ALB and Hyponatremia: Meta-analyses by Bernardi et al38,39 in 2012 and 2014 demonstrated that albumin was linked to a 15%–19% decrease in the likelihood of ascites recurrence, renal impairment, and hospital re-admissions and a risk reduction of PPCD by 61%, hyponatremia by 42%, and mortality by 36% compared with other therapies.